1. Home
  2. CCNE vs LTGO Comparison

CCNE vs LTGO Comparison

Compare CCNE & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNB Financial Corporation

CCNE

CNB Financial Corporation

SELL

Current Price

$33.38

Market Cap

1.0B

Sector

Finance

ML Signal

SELL

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$14.08

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CCNE
LTGO
Founded
1865
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
CCNE
LTGO
Price
$33.38
$14.08
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$38.00
★ $52.25
AVG Volume (30 Days)
116.6K
★ 359.2K
Earning Date
10-29-2026
11-19-2026
Dividend Yield
★ 2.25%
N/A
EPS Growth
★ 4.18
N/A
EPS
★ 1.79
N/A
Revenue
N/A
N/A
Revenue This Year
$25.41
N/A
Revenue Next Year
$5.38
N/A
P/E Ratio
$18.87
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.90
$14.60
52 Week High
$36.17
$25.93

Technical Indicators

Market Signals
Indicator
CCNE
LTGO
Relative Strength Index (RSI) 44.24 31.16
Support Level $32.84 N/A
Resistance Level $35.06 $20.49
Average True Range (ATR) 0.62 1.23
MACD -0.01 -0.21
Stochastic Oscillator 36.51 1.69

Price Performance

Historical Comparison
CCNE
LTGO

About CCNE CNB Financial Corporation

CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: